Celcuity Inc. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 32/100
What the filing says
Celcuity announced on October 2, 2026 the appointment of David W. Gryska to its Board of Directors. Gryska is a retired biotech executive with 35+ years of industry experience, including prior roles as CFO of Incyte Corporation and Celgene Corporation, and has served on boards of eight public biotechnology companies including 15+ years at Seagen Inc. The appointment is timed to support the company's transition to commercial-stage operations following FDA approval of REVTORPYK (gedatolisib) in advanced breast cancer.
Why this rating
Board appointment adds experienced CFO/governance expertise amid commercial launch; routine for biotech governance, not material to $457.5M market cap.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.